Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Lowered to Sell at StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Wednesday.

Oramed Pharmaceuticals Stock Down 4.7 %

Shares of ORMP stock opened at $2.22 on Wednesday. The company has a market cap of $89.49 million, a price-to-earnings ratio of 20.18 and a beta of 1.66. Oramed Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $3.67. The firm has a 50 day moving average of $2.34 and a 200-day moving average of $2.36.

Institutional Trading of Oramed Pharmaceuticals

Several hedge funds have recently bought and sold shares of ORMP. BML Capital Management LLC lifted its stake in Oramed Pharmaceuticals by 20.9% during the 4th quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock valued at $6,398,000 after acquiring an additional 457,716 shares in the last quarter. Murchinson Ltd. lifted its stake in Oramed Pharmaceuticals by 0.5% during the 3rd quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock valued at $4,170,000 after acquiring an additional 8,889 shares in the last quarter. Boothbay Fund Management LLC lifted its stake in Oramed Pharmaceuticals by 2.0% during the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company’s stock valued at $2,045,000 after acquiring an additional 16,857 shares in the last quarter. Peapod Lane Capital LLC bought a new position in Oramed Pharmaceuticals during the 4th quarter valued at $550,000. Finally, Dimensional Fund Advisors LP lifted its stake in Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 70,190 shares in the last quarter. Institutional investors and hedge funds own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.